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Background
In 2005, the DAMOCLES project ‘Issues in Data Monitoring and interim analysis of trials’, was published [1]. It established why and when Data Monitoring Committees (DMCs) are needed, their roles and responsibilities, structure, organisation, decision-making and reporting. DAMOCLES developed a comprehensive DMC Charter [2] which has impacted on an international collaboration across Canada, USA and Europe [3]. DAMOCLES defines the DMC as being advisory; its role being to make recommendations to an executive group. 

The Medical Research Council Guidelines for Good Clinical Practice (1998) [4] first defined a three committee trial oversight structure - the day-to-day Trial Management Group, the DMC and the Trial Steering Committee (TSC). In this model, the TSC is the executive committee that considers the recommendations from the DMC.  This structure is now required by many UK public funders, such as the National Institute for Health Research [5] and the Wellcome Trust [6]. Good Clinical Practice [7] (ref ICH E6) specifies that selection of members for oversight committees is the responsibility of the sponsor. Although operationally, clinical trials units suggest members and funders of clinical trials approve this selection. [4] [5]

There is no in-depth consideration establishing TSC role and functionality. The first guidance on TSC remit and structure was provided within the MRC Guidelines [4] but the extent to which this has been used is unknown. 

A survey to establish TSC current practice, requirements and the use and opinion on the MRC Guidelines was undertaken within UK Clinical Research Collaborative registered Clinical Trials Units. 

Methods
An invitation letter and survey were developed by EJC and CG and reviewed and piloted within the study team. 

Registered Units were identified from the Network website [8] on the 9th May 2013 (n=46, Supplementary File 1) [8]. Each Unit Director was invited by email to complete the survey. The survey was attached as a word document to be completed and returned by email, post or by telephone. Directors were asked to complete the survey or delegate completion to an experienced representative. Non-responders were re-contacted. Finally, members of the study team were asked to suggest and contact alternatives for non-responders. 

Survey 
The email included an invitation letter to explain the study (Supplementary File 2), a document containing the survey (Supplementary File 3) and a copy of the Guidelines on TSCs [4].

The survey comprised open and closed questions. Section A questions related to the development and use of their Units Terms (a document describing the committee remit, objectives and functionality), meeting frequency, constitution, and the relationship of the TSC with other committees and roles and responsibilities. Section B focussed on the existing Guidelines [4] requesting responders to identify additional items or aspects requiring improvement. Units were requested to provide a copy of their current Terms.

Analysis
Quantitative data from closed questions were analysed using descriptive statistics; no formal statistical testing was undertaken. Quantitative analyses were performed with standard statistical software [Statistical Analysis Software (SAS®) 9.1.3; SAS Institute Inc., Cary, NC, USA]. 

EJC and CG identified themes within the free text answers which were used to contextualise and illuminate quantitative responses. 

Terms provided by responders to the survey were examined using NVivo qualitative data analysis software [QSR International Pty Ltd. Version 10, 2012]. Coding, developed by EJC and CG, was applied to the Terms. 

To ensure anonymity, each Unit was assigned a project identification number. 

Results
The survey was conducted between 9th May 2013 and 17th September 2013. One Unit advised that their Unit was split across two individually managed units with different oversight procedures giving a maximum of 47 responses.

An 81% (38/47) response rate was achieved. Of the 9 non-responders 6 were fully registered and 3 provisionally. This is representative of the 47 contacted of which 69% (32/47) were fully registered.   Two Units declined to participate, providing reasons: TSC responsibility lies with the funder; and the wide diversity of trials within their Unit.

Survey results
Table 1 provides the survey results to closed items with open items summarised in Boxes 1-4. 

TSC Terms of reference
87% (33/38) of Units have a document in place (Question 1). Nearly all (30/33) stated they had utilised the Guidelines [4] (Question 1a) in its development with 10 indicating this as the only source.  A third indicated DAMOCLES [1] and a third in-house development. A minority of Units’ Terms were based on a collaboration with another Unit (2/33). Table 2 shows the combinations of sources of information used in developing Terms with 60% (20/33, 61%) using at least two sources.

TSC requirement
71% of Units required all RCTs to have a TSC (27/38, Question 2). Those that did not based requirement on funder or sponsor requirement; or trial characteristics such as size, complexity, duration, and risk. Reasons for not convening a TSC were pilot or feasibility study, experience from previous trials in the area and a well-characterised safety profile. 

The majority of Units have a separate TSC per trial. A quarter (9/38) used an umbrella model, a single TSC responsible for multiple trials (Question 3). 

Timings of meetings
The first TSC meeting was timed in relation to other milestones (Question 4). The majority specified timing in relation to recruitment (31/38), 27 before recruitment starts and four after. Of those indicating prior to recruitment, 18 timed this with finalising the protocol (17 prior, 1 post). Seven used other milestones: trial funding (5/38) and timing of the first DMC meeting (2/38).

Meeting frequency varied (Question 6). The majority (34/38) specified meeting at least annually, of which five required meetings at least every six months. One specified duration of 18 months, and three specified that meeting timings were trial dependent.

Three-quarters (29/38) timed meetings around DMC meetings (Question 7). Twenty-six specified meetings follow DMC meetings. Specifically: 1-2 weeks (4/26); 2-4 weeks (6/26) and 1-2 months (3/26). One stated this was trial dependent.

Three-quarters felt that the last TSC meeting should be held when the final results draft is available (28/38, Question 5). Other timings were follow-up completion (2/38) and following the last DMC (2/38). Six did not specify a timing stating it was trial dependent (4/38) or they had no policy in place (2/38).

The constitution of a TSC
The minimum number of independent members required (Question 9) ranged from one to six, where independence is defined as in the Guidelines as ‘not directly involved in the trial other than as a member of the TSC’. [4] The mode was a minimum of three (18/38), corresponding with the Guidelines. [4] Six (6/38) determined the number of independent members in relation to non-independent members. 13% (5/38) used the Health Technology Assessment guidelines of 75% independent representation [5], and one required more independent than non-independent members. 8% (3/38) stated it was trial dependent and 5% (2/38) did not answer.

One Unit required independent members only (Question 11). Those requiring non-independent members gave varying requirements from one non-independent member to more than four (14/38). Five specified a percentage of members (three 25%; two 66%). One-third stated this was trial specific (12/38) and six responses were unclear. 

A clinical lead expert, statistician or lay contributor was required for the majority (Question 10), with just under half of responders requiring all three on their TSCs (17/38). Lay contributors were indicated slightly more frequently than statisticians. One unit specified:
“An independent statistician on the TSC is always required in the absence of a DMC. For trials with a DMC, the DMC will always have an independent statistician and in some such cases the TSC will not have an additional independent statistician.”	[Responder 24]

Another stated they required statistical representation however, 
“An experienced triallist may be a substitute for a statistician”	[Responder 5]

Almost half (17/38) applied voting rights to non-independent members (Question 12) with 65% (11/17) ensuring that the balance of decision making power rested with independent members. In the remaining six the decision making power was unclear. Of Units not applying voting rights (21/38), ten ensured the majority of the committee were independent, four had the majority non-independent, six were unclear and one did not answer. Example responses to these questions are shown in Table 3. 

Two-thirds (25/38) specified when the TSC is quorate (Question 16). Ten required a minimum of two members, both independent (4/25) and with one non-independent (5/25). Ten stated a proportion to be quorate, one requiring 50% and nine following the Health Technology Assessment guidelines of a minimum of 67% independent members [5]. One Unit required all independent members plus the Chief Investigator in attendance and four units had no set rule. 

Identifying suitable TSC members
Responders approach to identifying members (Question 13) are summarised in Box 1 and indicate members are usually identified by recommendation. Difficulty in identifying appropriate members (Question 15) was most prominent in the statistical (17/38) and lay fields (15/38). 

One-third (13/38) shared circumstances wherein the statistician producing (performed analyses or oversaw and interpreted the analyses) the trials DMC closed report was also a TSC member (Question 20). Of these approximately half (6/13) reported that this was unavoidable due to staffing levels and experience.  One stated this dual role for the statistician caused a problem: 
“Concerns about bias and some level of anxiety for the statistician who is currently conducting the analyses blind to outcome (e.g. group A & B) but we have advised [the statistician] to not attend the TSC.”  [Responder 45] 

While four (three providing details) reported benefits of this dual role. Reasons were that the statistician was familiar with the trial and any issues that may occur (2/4) and 
“I would argue that on this occasion that it provided benefit – an urgent safety analysis was performed immediately following safety concerns (internationally co-ordinated) and the trial was stopped ultimately due to significant harm. So there may be occasions such as when safety might be an issue when such insight is beneficial.” [Responder 20]

Three-quarters (28/38) would prefer to avoid this dual role (Question 21). One commented this was because the decisions made could be influenced by emerging data trends. Four of the nine (9/38) who did not share this preference provided rationale: typically recruitment is completed long before the main endpoints are reached (1/9), a trial statistician serving on the TSC as a non-independent member would not have voting rights (1/9), the role of the statistician on the TSC is to address any study design issues and so the lead statistician is most suited for the role (1/9) and that problems arise when the trial statistician is not on the TSC (1/9). One respondent did not have a preference specifying that for blinded trials, committees should be separate as much as possible and in open-label trials, committees can be combined.

Experience required for TSC membership
Experience required for membership (Question 14, Box 2) was largely role dependent. 29% required the chair to have TSC membership experience (11/38) and 5% to have experience of chairing committees (2/38). Other members should be experienced triallists (9/38), an expert in their field (7/38) or be experienced in their field (5/38). Four had no formal criteria in place.

Five responders reported difficulties caused by inexperienced members (Question 19). One when a lay contributor did not understand processes. Another when inexperienced members requested outcome and unblinded data. Three related to the chair. 

Firstly, 
“A TSC chaired by someone new to TSCs. When a difficult situation arose with the DMC, the Unit was approached to advise and help resolve the situation. Also, some TSCs do not really seem to get to grips with the key issues in designing and delivering the trial, and so do not really fulfil their role as adequately as perhaps they might.” [Responder 19]

Secondly, 
“In one trial in particular the chair decided immediately prior to the first TSC meeting that she was not willing to chair the meetings. When a suggestion was made to replace the chair, the inexperienced members did not think this was necessary provided the ‘chair’ was present. The committee ultimately proved to be unfit for purpose and the trial suffered as a result.” 	[Responder 24]

Thirdly, 
“Some difficulties with an inexperienced chair re: remit of the TSC and chair.” [Responder 38]

TSCs communicating with other committees
Approximately 60% had joint TSC and DMC meetings (22/38, Question 8). These were held during trial set up or first meetings (15/22); to discuss important decisions such as major protocol changes or trial closure (3/22); when there is a disagreement (4/22) or when draft results are available (5/22). 

Direct communication with other committees was common (Question 17). Communication between the TSC and the Trial Management Group was most common (30/38), then the DMC (24/38) and the Unit (24/38). Less commonly, the TSC communicates with funders (15/38) and sponsors (12/38) upon matters other than that requested by the Unit.  

The roles of TSCs
The TSC are required to review (Question 18) main trial publications (23/38), the analysis plan (23/38) and the publication policy (22/38). Of documents suggested in the survey, eleven responders did not require their TSC to review any documents and two required the TSC review all. 

The TSC role extended to determining publications beyond the main report (16/38) and data sharing (16/38) (Question 22).

Medical Research Council Guidelines on TSCs
56% claimed to use the Guidelines [4] (20/38) as provided. Twenty suggested aspects of these that need improving or incorporating. Suggestions were not limited to those who used the Guidelines and are summarised in Box 3. 

Terms 
33 Units have Terms (Question 1), of which two-thirds (21/33) provided a copy (Question 23). Two returned documents describing umbrella TSC models and were considered separately.

Format and scope
Five Terms were presented in a two column format, following DAMOCLES [2] and 14 used an essay style layout. The median length was four pages and ranged from 1 to 18 pages (excluding title pages and sign off sheets). One was a general document for all oversight committees, one described a Trial Oversight Committee – a committee of a TSC and DMC merged - and one was a template document adaptable to both umbrella and single trial TSCs. Two Terms were unchanged from the guidelines provided by the applicable funder (Health Technology Assessment [5] and Efficacy and Mechanism Evaluation [9]).
  
Seven outlined the scope using suggested text in the DAMOCLES DMC charter [2]. 

Role
Six documents stated members will be named with their affiliations in publications, unless specifically requesting otherwise. 

Members were commonly required to maintain confidentiality of trial information not already in the public domain. Members were requested to destroy or store safely information and materials following meetings, again this corresponds to the DAMOCLES Charter [2]. 

Membership
When appointed, members are generally required to register their agreement to join the group and declare competing interests. Terms discussing replacing members took guidance from DAMOCLES [2]. Only one discussed who was responsible for replacing members, stating this to be the TSC. Terms unchanged from those provided by the funder [5] [9] described a funder role in appointing independent members, where the trial team suggests members to the funder who then vets and appoints members. 

Two did not indicate a chair. Two followed Efficacy and Mechanism Evaluation guidelines [9] specifying all TSCs have an independent chair. Three defined the role of the chair using a list from the Health Technology Assessment guidelines [5]. 

Ten Terms discussed observers, members without voting rights, not part of the trial team and not expected to input into discussion. Who observers are and when they should they attend was generally in consensus between Terms and in line with existing funder guidelines [4] [5] [9]. The Sponsor, Funder and Host Institution (or trial staff within) were commonly invited to meetings. Additional observers may be invited at the discretion of the TSC or TSC chair.

Only two defined independence. Six Terms defined conflicts of interest, stating that any conflicts of interest of any member should be disclosed utilising the definition in DAMOCLES [2]. 

Five covered payment of members. Of which four followed DAMOCLES [2], stating no payment or reward will be granted though members will be reimbursed for expenses. One charter stated honoraria for lay members. 

Terms describing an umbrella model (n=2) specified a tenure that membership is expected to last at least three years. 

Meetings
Five generalised that the trial team prepare the TSC report whereas others specified this be done by the statistician (n=1), trial coordinator (n=1) and trial manager (n=1). Timing of distributing the report varied from 1-2 weeks prior to the meeting with some generalising that the report be distributed prior to the meeting. In two cases the TSC agree a report template and three used the Guidelines template [4]. Reviewing external evidence was commonly required which should be forwarded as appropriate between meetings. 

Following DAMOCLES [2], the first meeting should be face to face and subsequent face to face meetings are preferred though not essential. No charter indicated the timing of the last meeting. 

Decision making
Commonly, the TSC was responsible for making decisions regarding future continuation of the trial and major changes to the protocol/trial design. This duty is listed in funder guidelines [4][5]. Listing possible decisions, similar to the list in DAMOCLES [2], was another widespread approach. Six grant the TSC responsible for approving external or early internal requests for release of data, as in DAMOCLES [2].    

Decisions by consensus is commonly required. Following Health Technology Assessment guidelines [5], the chair was often given the casting vote with one stating that when consensus is not reached the decision should be escalated to the Sponsor. 


Organising meetings and between committee communication
There was variation as to who organises meetings and takes minutes. The responsibility fell to the Trial Manager (n=6), Chief Investigator (n=3), Trial Coordinator (n=2), Principal Investigator (n=2) and/or another member of staff at the Unit (n=1). Seven defined this role as a facilitator. The facilitator was central to all communications within and between the TSC. 
Four illustrated between committee relationships with a diagram as DAMOCLES recommended [2]. Following the Health Technology Assessment guidelines [5] others stated that the chair of the TSC (or the TSC as a unit) should determine a communication strategy. 

Three gave guidance on timing of when the TSC should report their decisions all adopting the within three weeks DAMOCLES guidance [2].

Dealing with conflict 
Five guided on conflict between the DMC and TSC with all suggesting a joint meeting to be held if necessary. Four followed the illustrative example in the DAMOCLES Charter [2].

Discussion
We achieved an 81% (38/47) response rate providing insight into the general and current practice of TSCs within the UK.  TSC value in these academic Units could be inferred by the high participation willing to assist in developing a comprehensive document. TSC existence outside of the UK is not known. However, Good Clinical Practice [7] states that “An independent data-monitoring committee that may be established by the sponsor […] to recommend to the sponsor whether to continue, modify, or stop a trial.” We would argue that the benefit of a TSC is its ratio of dependent/independent members to aid objective consideration of the recommendations from the DMC and as such this should be internationally adopted. Without such a committee DMC recommendations may be overturned due to vested interests. The principal governmental agency for health research in the United States, the National Institute of Health, does not advocate the use of TSCs. It instead requires an executive Data Safety Monitoring Board to both make recommendations and decide by voting on these recommendations about starting, continuing or stopping a study communicating these decisions in a report to the Data Coordinating Centre [14]. 

The survey highlighted the widespread adoption of DAMOCLES [2] within the UK publicly funded trials. Results indicated that the Medical Research Council Guidelines [4] are commonly used as a reference in developing Terms for TSCs. We identified improvements, amendments and gaps within these Guidelines that need to be addressed in their redevelopment. Other funder guidelines are also widely used, but requirements across available guidelines are not consistent resulting in heterogeneity in practice across Units. Building upon the detail in existing guidelines and gaining agreement on their content across stakeholders should reduce the level of diversity in trying to adhere to best practice and funder/sponsor requirements, and allow developments in TSC role such as in data sharing and to be recognised. This highlights the value and need in the development of a single generic document and its widespread usage. 

The perceived executive decision-making role of the TSC could be challenged as being artificial. Sponsors and funders may be the true executive for continuation as they have (and sometimes exercise) the power to withdraw funding and so have the potential to override decisions made by the TSC, effectively removing the power of independent oversight. In addition, requirements have arisen from large public funding bodies that they have involvement in the selection process; formally inviting members, reserving the right to veto membership and consider the independent members to provide funder representation. Although this may be considered reasonable, for publicly funded trials, it highlights uncertainty around who the TSC actually works for and therefore its independence. This is a key point requiring further consideration. 

The potential dual role of statisticians involved in the preparation of closed DMC reports and TSC membership needs careful consideration. Three-quarters of units felt it was preferable to avoid this. Problems associated with the dual role provided were in relation to external perceptions and the anxiety imposed on the unblinded statistician rather than relating to issues of bias.  However, the requirement for separation has resource implications and potential disadvantages with loss of in-depth knowledge.  It was clear from some responses that this was managed by allowing the practice but avoiding assignment of voting rights.

There is great variation in the use of voting rights for non-independent members. Only 15% of units follow the Health Technology Assessment guidelines of 75% independent representation [5]. The consequence of this requirement is that the number of members required can quickly become impractically large when ensuring that this ratio requirement is met and leaves little scope for adaptation. This could be overcome by labelling voting members as true members of the TSC with non-voting members being observers. However, the potential for non-voting members to exert influence needs consideration. The majority ensure that where voting rights are used the balance of decision making power rests with the independent members.  

One Unit commented that a directory of experienced DMC/TSC members by region would be useful (Box 1) and over 40% of responders stated that had difficulty identifying members with appropriate experience to act as statistical and lay representation.  A difficulty that should be considered against research suggesting that lay representation, while required by funders, may be tokenistic. [10]

It is clear from the survey that an umbrella model for TSCs is often used, that is where one TSC is convened to monitor a number of trials, with one quarter of units reporting this approach and two responders used only this approach. It is important that guidelines developed reflect this and are adaptable for such an approach. 

Although this survey was limited to registered Units, responders represent wide geographic coverage within the UK, spanning a diverse range of medical conditions and associated methodology, [11] and are known to comply with required regulatory standards and meet acceptable standards of quality. [12] Publicly funded trials cover a diversity of interventions [13] and are generally not seeking a marketing authorisation from the competent authorities. All responders were therefore experienced triallists being either Unit Directors or being delegated by their Unit Director to participate. An acknowledged limitation is that funders and sponsors were not involved however, where available, their Terms were used as a reference throughout. Although the survey allowed for free text responses more in depth responses could have been achieved by qualitative research methods. An ethnographic study has also been conducted and informed by the survey. [14] The extent of the translation of this work beyond the UK will be dependent upon international oversight requirements. 

Conclusions
This survey is the first to report on the experience and remits of TSCs within the UK and while identifying widespread adoption of Medical Research Council Guidelines [4], limitations have also been identified. This survey supports the redevelopment and expansion of these guidelines. 
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Table 1 – Responses to closed items in survey
Question No	Question	Answer	Answer statistics n/N (%)
			n	N	n/N%
	SECTION A		
1		Do you have a Terms that is used for randomised controlled trials coordinated by your Unit?		Yes	33	38	87%
			No	5	38	13%
	a	If yes, was this based on (tick all that apply):	Medical Research Council Guidelines on TSCs	30	33	90%
			DAMOCLES	13	33	39%
			In house	14	33	44%
			Collaboration with another unit	2	33	6%
			Further analysis of responses to Q1A given in Table 2
2		Do you specify that every randomised controlled trial requires a Trial Steering Committee?	Yes	27	38	71%
			No	11	38	29%
3		Do your trials have: 	Each trial has own independent Trial Steering Committee	29	38	76%
			A single Trial Steering Committee responsible for monitoring all trials	2	38	5%
			Both approaches taken	7	38	18%
5		When should the last Trial Steering Committee meeting be held?	When follow up completed	2	38	5%
			During final data cleaning process	0	38	0%
			When final results draft available	28	38	74%
			Trial dependent	4	38	11%
			Following last Data Monitoring Committee meeting	2	38	5%
			No policy in place	2	38	5%
7		Are the timings of the meetings set in relation to Data Monitoring Committee meetings	Yes	29	38	76%
			No	9	38	24%
8		Do you ever have joint meetings of the Trial Steering Committee and Data Monitoring Committee	Yes	22	38	58%
			No	16	38	42%
10		Do you require independent representation on your Trial Steering Committees for the following:	Statistician	24	38	63%
			Clinical lead expert	35	38	92%
			Patient and public involvement (lay representation)	28	38	71%
			Further analysis of responses to Q10 given in Table 3
12		Do you apply voting rights to non-independent members?	Yes	17	38	45%
			No	21	38	55%
15a		How difficult do you find identifying members with appropriate clinical experience?	Difficult	7	38	18%
			Easy	15	38	39%
			Neither	15	38	39%
			Not applicable/specified	1	38	3%
15b		How difficult do you find identifying members with appropriate statistical experience?	Difficult	17	38	45%
			Easy	4	38	11%
			Neither	13	38	34%
			Not applicable/specified	4	38	11%
15c		How difficult do you find identifying appropriate lay representatives?	Difficult	15	38	39%
			Easy	6	38	16%
			Neither	15	38	39%
			Not applicable/specified	2	38	5%
16		Do you specify when the Trial Steering Committee is quorate?	Yes	25	38	66%
			No	13	38	34%
17		Who should the Trial Steering Committee communicate with directly	Data Monitoring Committee	24	38	63%
			Trial Management Group	30	38	79%
			Clinical Trials Unit	24	38	63%
			Funders - for communication other than that requested by the Trial Management Group or Clinical Trials Unit	15	38	39%
			Sponsors - for communication other than that requested by the Trial Management Group or Clinical Trials Unit	12	38	32%
			Further analysis of responses to Q17 given in Table 4
18		Do you require your Trial Steering Committee review any of the following trial documents?	Data monitoring plan	7	38	18%
			Data Monitoring Committee report plan	11	38	29%
			Risk assessment	9	38	24%
			Publication policy	22	38	58%
			Statistics analysis plan	23	38	61%
			Main trial publications	23	38	61%
			Further analysis of responses to Q18 given in Table 5
	a	Please specify any other trial documents, not listed in Q18, which you require your Trial Steering Committee to review?	Protocol	11	38	29%
			Statistical analyses (blind)	2	38	5%
			Patient information leaflets	2	38	5%
			Case Report Forms	2	38	5%
			Questionnaires	1	38	3%
			Sub studies	1	38	3%
			Sub analyses	1	38	3%
			Data Monitoring Committee charter	1	38	3%
			Trial Steering Committee charter	1	38	3%
			Risk assessment	1	38	3%
19		Have you ever experienced any difficulties caused by inexperienced Trial Steering Committee members?	Yes	5	38	13%
			No	33	38	87%
20		Have statisticians who are involved in producing the trials Data Monitoring Committee closed report ever also been a Trial Steering Committee member?	Yes	13	38	34%
			No	25	38	66%
	a	If yes, was this unavoidable due to staffing levels/experience?	Yes	6	13	46%
			No	7	13	54%
	b	If yes, has this ever caused a problem/benefit?	Yes	5	13	38%
			No	8	13	62%
21		Do you believe it is preferable to ensure that the statisticians involved in producing the Data Monitoring Committee closed report are not a member of the Trial Steering Committee	Yes	28	38	74%
			No	9	38	24%
			Neither	1	38	3%
22a		Does your Trial Steering Committee have a role in determining additional publications to the main report	Yes	16	38	42%
			No	22	38	58%
22b		Does your Trial Steering Committee have a role in data sharing?	Yes	16	38	42%
			No	22	38	58%
23		Has Terms and willing and have permission to provide a copy? 	Yes	21	33	64%
			No	12	33	36%
	SECTION B		
1		Do you currently use the Medical Research Council Guidelines on Trial Steering Committees (1998) in their current format? NB: A copy is attached to this survey.	Yes	20	38	56%
			No	14	38	39%
			Neither	2	38	6%



Table 2 - Section A, Question 1a: If you have a Terms, what was this based on?
Number of sources checked	Number of sourcesstatistics(N=33)	Terms of reference source options	Source combinationstatistics(N=33)
		Medical Research Council Guidelines for Trial Steering Committees	DAMOCLES	In house	Collaboration with another Unit	
	n	n/N%					n	n/N%
0	1	3%					1	3%
1	12	36%	X				10	30%
				X			1	3%
					X		1	3%
2	14	42%	X	X			7	21%
			X		X		7	21%
3	5	15%	X	X	X		4	12%
			X		X	X	1	3%
4	1	3%	X	X	X	X	1	3%
Total using source	30	13	14	2			
NB: Only combinations specified by responder have been included in table.
Table 3 – Interpreting balance of power between independent and non-independent members - Examples of responses to Question 9, 11 and 12. 
Balance of power	Responder ID	Q12. Do you apply voting rights to non-independent members?	Q9. How many independent members do you require on your Trial Steering Committee?	Q11. How many non-independent members do you require on your Trial Steering Committee?
Independent members	Responder 8	Yes	3+	2 or 3
Non-independent members	Responder 25	No	3 independent clinicians and a consumer	6
Unclear	Responder 13	Yes	It is not pre specified but decided for each individual trial.	It is not pre specified but decided for each individual trial.




Table 4 - Section A, Question 10: Do you require independent statisticians, clinical lead experts or lay representation on your Trial Steering Committees?
Number of roles checked	Number of rolesstatistics(N=38)	Role options	Role combinationstatistics(N=38)
		Statistician	Clinical lead expert	Lay representation	
	n	n/N%				n	n/N%
1	3	8%		X		3	8%
2	16	42%	X	X		6	16%
			X		X	1	3%
				X	X	9	24%
3	17	45%	X	X	X	17	45%
Total requiring role	24	35	27			
NB: Only combinations specified by responder have been included in table.	

Box 1 - Section A, Question 13: How do you identify potential Trial Steering Committee members?




Box 2 - Section A, Question 14: What level of experience do you require from Trial Steering Committee members?





Table 5 - Section A, Question 17: Who should the Trial Steering Committee communicate with directly?
Number of communications checked	Number of communicationsstatistics(N=38)	Communication options	Communications combinationsstatistics(N=38)
		Data Monitoring Committee	Trial Management Group	Unit	Funders	Sponsors	
	n	n/N%						n	n/N%
1	5	13%	X					1	3%
				X				2	8%
					X			2	8%
2	12	32%	X	X				4	11%
			X		X			2	8%
				X	X			5	13%
				X		X		1	3%
3	13	34%	X	X	X			4	11%
			X	X		X		2	8%
			X	X			X	1	3%
			X		X	X		1	3%
			X			X	X	1	3%
				X	X	X		1	3%
				X	X		X	2	8%
					X	X	X	1	3%
4	3	8%	X	X	X	X		1	3%
			X	X		X	X	2	8%
5	5	13%	X	X	X	X	X	5	13%
Total selecting communication	24	30	24	15	12		
NB: Only combinations specified by responder have been included in table.




Table 6 - Section A, Question 18: Do you require you Trial Steering Committee review any of the following trial documents?
Number of documents checked	Number of documents statistics(N=38)	Document options	Document combinationstatistics(N=38)
		Data monitoring plan	Data Monitoring Committee report plan	Risk assessment	Publication policy	Statistics analysis plan	Main trial publications	
	n	n/N%							n	n/N%
0	11	29%							11	29%
1	1	3%						X	1	3%
2	2	5%					X	X	2	5%
3	12	32%	X		X		X		1	3%
			X		X		X		1	3%
				X	X	X			1	3%
				X		X	X		1	3%
				X			X	X	1	3%
						X	X	X	8	21%
4	8	21%	X		X	X		X	1	3%
			X			X	X	X	1	3%
				X	X	X	X		1	3%
				X	X	X		X	1	3%
				X		X	X	X	2	5%
					X	X	X	X	2	5%
5	2	5%	X	X		X	X	X	2	5%
6	2	5%	X	X	X	X	X	X	2	5%
Total selecting document	7	11	9	22	23	23		
NB: Only combinations specified by responder have been included in table.



Box 3 – Section B, Question 2: Aspects of the Medical Research Council Guidelines [4] that should be incorporated or improved

References
[1] 	Grant A,  Altman D, Babiker A, et al. Issues in data monitoring and interim analysis of trials. Health Technology Assessment 2005; 9(7).
[2]	DAMOCLES Study Group. A proposed charter for clinical trial data monitoring committees: helping them to do their job well. The Lancet 2005; 365 (9460).
[3] 	Chan A, Tetzlaff J, Gøtzsche P, et al. SPIRIT 2013 explanation and elaboration: guidance for protocols of clinical trials. BMJ 2013; 346(7586).
[4]	MRC Guidelines for Good Clinical Practice in Clinical Trials. Online referencing. Available: www.mrc.ac.uk. (1998, accessed 10 November 2014).
[5]	National Institute for Health Research Health Technology Assessment Programme: Study Steering Committee or Trial Steering Committee, 2012. 
[6]	Wellcome Trust policy position on clinical trials. Online referencing. Available: http://www.wellcome.ac.uk. (2013, accessed 10 November 2014).
[7] 	International Confernce on Harmonisation of Technical Requirements for Registration of Pharmaceuticals for Human Use. ICH Harmonised Tripartite Guidelines: Guideline for Good Clinical Practice E6(R1). 1996. Online Referencing. Available: http://www.ich.org/fileadmin/Public_Web_Site/ICH_Products/Guidelines/Efficacy/E6/E6_R1_Guideline.pdf (​http:​/​​/​www.ich.org​/​fileadmin​/​Public_Web_Site​/​ICH_Products​/​Guidelines​/​Efficacy​/​E6​/​E6_R1_Guideline.pdf​). (Accessed 27th February 2015).  
[8]	UKCRC Registered Clinical Trials Units Network. Online referencing. Available: http://www.ukcrc-Unit.org.uk. (Accessed 9 May 2013).
[9]	National Institute for Health Research Efficacy and Mechanism Evaluation Programme. Research Governance Guidelines. Online referencing.  Available: http://www.nets.nihr.ac.uk.. (Accessed 10 November 2014).
[10]	Buck DB, Gamble C, Dudley L, et al. From plans to actions in patient and public involvement: qualitative study of documented plans and accounts of researchers and patients sampled from a cohort of clinical trials. BMJ Open 2014; 4(12). 
[11]	Brown J, Bashir S, Rudkin S, et al. Experience and Benefits arising from the United Kingdon Registered Clinical Trials Unit Network. Clinical Trials. Epub ahead of print November 2014.
[12]	McFadden E, Bashir S, Canham S, et al. The impact of registration of clinical trials units: The UK experience. Clinical Trials. Epub ahead of print December 2014.
[13]	Gamble C, Dudley L, Allam A, et al. Patient and public involvement in the early stages of clinical trials development: a systematic cohort investigation. BMJ Open 2014; 4(7). 
[14]	Daykin A, Heawood A, Lane A, et al. An ethnographic study of group decision making to understand and improve how trial steering committees contribute to trial conduct. 2nd Clinical Trials Methodology Conference: Methodology Matters, Edinburgh, 2013. 
[14]	National Institute of Health Toolkit for Clinical Researchers Data and Safety Monitoring Board (DSMB) Guidelines. Online referencing. Available: http://www.nih.gov. [Accessed 10 November 2014].


Recommendations by:
Chief Investigator (18/38, 47%); Principal Investigator (2/38, 5%); Funder (6/38, 16%); Sponsor (4/38, 11%); Unit (8/38, 21%); Colleagues/contacts of Unit (2/38, 5%); Trial team (4/38, 11%); Grant holders (2/38, 5%); Collaborators (1/38, 3%); Trial statistician (1/38, 3%); Unit steering committee (1/38, 3%); Members of research team (1/38, 3%)
Identified from:
Colleagues from previous trials (7/38, 18%); Experts in field (8/38, 21%); List of ex TSC members (1/38, 3%); Research networks (e.g. National Institute for Social Care and Health Research Registered Research Groups, Involve, Involving people, United Kingdom Clinical Research Collaborative Trials Unit Networks) (1/38, 3%); Literature/web search (1/38, 3%)
Lay representation identified from: Charity (2/38, 5%); Patient support groups (5/38, 13%); Past trial participants (2/38, 5%)
Other:
One responder commented that a directory of experienced DMC/TSC members by region would be useful. 



General membership
	Expert in field (7/38, 18%)
	Experience in own field (5/38, 13%)
	Experienced triallist (9/38, 24%)
	Trial management experience (3/38, 8%)
	Served on oversight committees in past (e.g. Trial Management Group or Trial Steering Committee) (1/38, 3%)
	Relevant and appropriate for the trial and individual role on Trial Steering Committee. (4/38, 11%) 
	Experience of serving on a Trial Steering Committee (1/38, 3%)
	At least one member have considerable experience of trials and Trial Steering Committee s for trials (1/38, 3%)
Chair
	Chair required to have Trial Steering Committee membership experience (11/38, 29%)
	Experience of chairing committees (2/38, 5%)
	Experience of running trials (1/38, 3%)
	Experience in field (1/38, 3%)
	Chair and vice chair required to have trial committee membership experience (1/38, 3%)
Lay representatives
	Advertised and interviewed for experience of field, research, grants and ability to review paperwork (1/38, 3%)
No criteria
	No formal criteria (4/38, 11%)
	Response not clear (3/38, 8%)


Content of Medical Research Council Guidelines
a.	Guidelines operationalised by changing to charter
b.	Incorporate comprehensive guide for Trial Steering Committee membership provided by National Institute of Health Research Health Technology Assessment (2012) [5] and template by DAMOCLES [2]

Membership
a.	Clarify membership of voting/non-voting members as in National Institute of Health Research Health Technology Assessment guidelines [5] 
b.	State and justify independent/non-independent ratio
c.	Training/experience required to chair/be member of Trial Steering Committee

Meetings
a.	Who should organise? Medical Research Council guidelines confusing as states Principal Investigator though Chief Investigator responsible for trial.
b.	Who should prepare minutes? Medical Research Council guidelines state Principal Investigator though this isn’t often practical.
c.	What info should be viewed by independent Trial Steering Committee members, if any?

Role of Trial Steering Committee
a.	Serious breaches role
b.	Role of independent and non-independent members
c.	Role in applying for extension (funded or non-funded)
d.	Better terminology of non-independent members and observers
e.	Should compliance be reviewed by Trial Steering Committee, expand on Medical Research Council
f.	Trial Steering Committee role in responding to suspected misconduct
g.	How Trial Steering Committee should make decisions, such as changing sample size, difference to detect, or primary endpoint

Other
a.	When Trial Steering Committee s are not appropriate
i.	Complex intervention trials or long duration trials
ii.	Can Data Monitoring Committee ever be subgroup of Trial Steering Committee?
iii.	Can Trial Steering Committee and Data Monitoring Committee ever be one committee?
b.	Flexible guidance on single or multi-trial Trial Steering Committee 
i.	When appropriate
ii.	Difference in information shown to either Trial Steering Committee format
c.	Dealing with disagreements
i.	Within committees: Trial Steering Committee, Data Monitoring Committee and Trial Management Group
ii.	Between committees: Trial Steering Committee, Data Monitoring Committee and Trial Management Group and/or Chief Investigator

Other committees
a.	Data Monitoring Committees
i.	When Data Monitoring Committee reveal information to the Trial Steering Committee, who should receive it? Independent members only?
ii.	Can Trial Steering Committee ever assume role of Data Monitoring Committee?
b.	Funder and sponsor
i.	Often seen as ‘true’ executive for continuation of trial as wield the power to withdraw funding so should be added to charter
ii.	Better define relationship between the two, with strong mutual reassurances, and with Trial Steering Committee
iii.	Should they attend meetings?
iv.	Should they have the power to veto members?
v.	Independence issue, neither independent though both can overrule decisions.
vi.	When applying for extensions, should funder/sponsor representative have power to vote?
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